[01] C. E. Sokwaibe, Department of Chemistry, Michael Okpara University of Agriculture, Umudike, Nigeria. [02] I. E. Otuokere, Department of Chemistry, Michael Okpara University of Agriculture, Umudike, Nigeria.

Zinc(II)1-(5-Hydroxy-3-methyl-1-phenyl-1-pyrazol-4-yl)octadecan-1-one complex was synthesized by the reaction of 1-(5-Hydroxy-3-methyl-1-phenyl-1-pyrazol-4-yl)octadecan-1-one with zinc(II)sulphate heptahydrate. A dirty-white precipitate with a melting point of 310°C was isolated. The complex was insoluble in water but soluble in organic solvent. The molar conductance value of the complex was 4.8 Siemens mol^-1cm^-1 which suggested that the complex is covalent. Infrared, ¹HNMR and ¹³CNMR characterization showed that the complex is tetrahedral. The results of the anti-prostatic hyperplasia studies showed a significant increase (P<0.05) in Prostate specific antigen (PSA) value of hormone control group (HC) receiving only hormonal induction relative to [Zn.HMPPO.H₂O] group. Serum prostatic acid phosphatase activity (PACP) showed a significant increase (P<0.05) in ‘HC’ Group receiving only hormonal induction relative to [Zn.HMPPO.H₂O] group. Relative prostate weight was significantly increased (P<0.05) in ‘HC’ group compared to [Zn.HMPPO.H₂O] group. We deduced that zinc (II)1-(5-Hydroxy-3-methyl-1-phenyl-1-pyrazol-4-yl)octadecan-1-one inhibited the growth of benign prostatic hyperplasia.

Zinc(II)1-(5-Hydroxy-3-methyl-1-phenyl-1-pyrazol-4-yl)octadecan-1-one, Benign Prostatic Hyperplasia, Complex, Characterization

[01] Hashimoto, R., Fujimaki, K., Jeong, M. R., Senatorov, V. V., Christ, L., Leeds, P., Chuang, D. M., Takeda, M. (2003). Neuroprotective actions of lithium. SeishinShinkeigaku Zasshi, 105(1): 81-86. [02] Zheng, Y., Sanche, L. (2009). Gold nanoparticles enhance DNA damage induced by anti-cancer drugs and radiation. Radiat. Res. 172(1): 114-119. [03] Kapoor, S. (2009). Lanthanum and its rapidly emerging role as an anticarcinogenic agent. J. Cell Biochem. 106(2): 193. [04] Ansari, K. I., Grant, J. D., Kasiri, S., Woldemariam, G., Shrestha, B., Mandal, S. S. (2009). Manganese (III)-salens induce tumor selective apoptosis inhuman cells. J. Inorg. Biochem. 103(5): 818-826. [05] Balk, E. M., Tatsioni, A., Lichtenstein, A. H., Lau, J., Pittas, A. G. (2007). Effect of chromium supplementation on glucose metabolism and lipids. A systematic review of randomized controlled trials. Diabetes Care. 30(8): 2154-2163. [06] Lange, T. S., Kim, K. K., Singh, R. K., Strongin, R. M., McCourt, C. K., Brard, L. (2008). Iron (III)-salophene: an organometallic compound with selective cytotoxic and anti-proliferative properties in platinum-resistant ovarian cancer cells. PLoS One. 3(5): e2303. [07] Ray, S., Mohan, R., Singh, J. K., Samantaray, M. K., Shaikh, M. M., Panda, D., Ghosh, P. (2007). Anticancer and antimicrobial metallopharmaceutical agents based on palladium, gold, and silver N-heterocyclic carbine complexes. J. Am. Chem. Soc. 129(48): 15042-15053. [08] Sun, Q. vanDam, R. M., Willett, W. C., Hu, F. B. (2009). Prospective study of zinc intake and risk of type 2 diabetes in women. Diabetes Care. 32(4): 629-634. [09] Au, L., Zheng, D., Zhou, F., Li, Z. Y., Li, X., Xia, Y. (2008). A quantitative study on the photothermal effect of immuno gold nanocages targeted to breast cancer cells. ACS Nano. 2(8): 1645-1652. [10] Bassetti, S., Hu, J., Agostino Jr., R. B., Sherertz, R. J. (2001). Prolonged anti microbial activity of catheter containing chlorhexidine silver sulfadiazine extends protection againsts catheter infection in vivo. Antimicrob Agent Chemother. 45(5): 1535. [11] Lorisean, P. M., Carciunescu, D. G., Doadrio Villarejo, J. C., CertadFombona, G., Gayyal, P. (1992). Pharmacomodulation of new organometallic complexes of Ir, Pt, Os, Rh, Pd: in vivo and in vitro trypanocidal study against trypanosomabruccibrucci. Trop. Med. Parasito. 43(2): 110- 114. [12] Fukushima, T., Horike, H., Fujiki, S., Kitada, S., Sasaki, T., Kashihara, N. (2009). Zinc deficiency anemia and effects of zinc therapy inmaintenance hemodialysis patients. Ther.Apher. Dial. 3: 213-219. [13] Saji, H., Kinoshita, T., Kubota, M., Kaneda, K., Akaike, A., Kikuchi, M., Kashii, S., Honda, Y., Iida, Y., Magata, Y. and Yokoyama, Y. (1997). Brain permeable zinc complex with neuroprotective action, S. T. P. Pharma Sci., 7: 92-97. [14] Mossad, S. B., Macknin, M. L., Medendorp, S. V. and Mason, P. (1996). Zinc gluconate lozenges for treating the common cold: a randomized, double-blind, placebo-controlled study. Ann Intern Med. 125: 81–88. [15] Macknin, M., Piedmonte, L., Calendine, M., Janosky, C. J., Wald, E.(1998). Zinc gluconate lozenges for treating the common cold in children. JAMA. 279: 1962–1967. [16] Ross, G. M., Shamovsky, I. L., Lawrance, G., Solc, M., Dostaler, S. M., Jimmo, S. L., Weaver, D. F., andRiopelle, R. J. (1997). Zinc alters conformation and inhibits biological activities of nerve growth factor and related neurotrophins, Nature Med., 3: 872-878. [17] Huang, E. D. (1997) Metal ions and synaptic transmission: think zinc, Proc. Natl. Acad. Sci. USA, 94: 13386-13387. [18] Multhaup, G., Bush, A. I., Dollwein, P., and Masters, C. L. (1994). Interaction between the zinc(II) and the heparin binding site of the Alzheimer's disease βA4 amyloid precursor protein (APP), FEBS Lett., 355: 151-154. [19] Singh, R. V. and Chaudhary, A. (2004). Biologically relevant tetraazamacrocyclic complexes of manganese. Spectral, antimicrobial, antifertility, and anti-inflammatory approach. J. InorgBiochem. 98(11): 1712-1721. [20] Sokwaibe, C. E. and Otuokere, I. E. (2016). Synthesis, Characterization and Anti- prostatic Hyperplasia Activity of 1-(5-Hydroxy-3-methyl-1-phenyl-1h-pyrazol-4- yl)octadecan-1-one, International Journal of Chemical Engineering and Analytical Science, 1(1): 42–48. [21] Ehirim, A. I. C., Elenwoke, U. E. and Ogwuegbu, M. O. C. (2014). Synthesis and Spectroscopic Studies of 4-butanoyl-3- methyl-1-phenylpyrazol-5-one and its Manganese (II), Lanthanum (III), Zirconium (III), Vanadium (V) and Tungsten (VI) complexes. International Journal of Science and Research. 3: 720. [22] Ogwuegbu, M. O. C. (1999). Synthesis and Characterization of Nitroacyl-5-oxo-pyrazole and its Vanadium (V), Iron (III) and Cobalt (II) complexes, Bull. Chem. Soc. Ethiop., 13(2), 113—120. [23] Ahaiwe, U (2012). The effect of oral administration of leaf extract of VernoniaAmygdalina on benign prostatic hyperplasia in rats. A Thesis of Biochemistry Dept. MOUAU. [24] Henry, J. B. (1979). Clinical diagnosis and management by laboratory methods, W. B. Saunder Company, Philadelphia, PA, 1: 60. [25] Uzoukwu, B. A. (1993). Spectroscopic Study of Manganese (II) and Zinc (II) Complexes with Some 4-acyl Derivatives of 1-phenyl-3-methyl-4-acylpyrazolone-5, Spectrochim. Acta, 49A: 281 282. [26] Uzoukwu, B. A. (1993). Synthesis and Characterization of Cobalt (II) complexes with some 4-acyl derivatives of 1-phenyl-3-methylpyrazolone-5, Synth. React. Inorg.Met.-org.Chem., 20: 1071. [27] Yam, J. V (2007). The search for bioactive compound in tropical plants to target hormonal imbalance associated disease. Inaugural dissertation, Singapore. [28] De La Rosette, J., Alivizatos, G., Madersbacher, S., Rioja, S. C., Nordling, J., Emberton, M., Gravas, S., Michelm, M. C., Oelke, M. (2006). Guidelines on benign prostatic hyperplasia. European Association of Urology. 40: 672–676. [29] David, A. A. (1993). Prostate – SpecificAntigen: Biochemistry Analytical methodsand clinical Application. Clin.Chem. 39(2): 181–195. [30] Joshua, P. E., Obidoa, O., Nwodo, F. C. (2010). Biochemical responses of rat prostate to coconut (cocosnucifera) milk ingestion/treatment. NJBM. 25(1): 1-8. [31] Jeyaraj, D. A., Uduyakumar, T. S., Rajalakshmi, M., Pal, P. C., Sharma, R. S. (2000). Effect of long administration of androgens and estrogen on rhesus monkey prostate: possible induction of benign prostatic hyperplasia. J. Androl. 21: 833–841. [32] Leite Ferreira, B. J. M., Brandão, P., Meireles, M., Fátima M., Correia-Branco, A., Diana M. F., Santos, T. M., Félix, V. (2016). Synthesis, structural characterization, cytotoxic properties and DNA binding of a dinuclearcopper(II) complex. Journal of Inorganic Biochemistry161: 9-17. [33] JunGang, D., Yi, G., Wei, C., Xiang, F., Hang, D. (2016) The Cu/ligand stoichiometry effect on the coordination behavior of aroylhydrazone with copper (II): Structure, anticancer activity and anticancer mechanism. Bioorganic & Medicinal Chemistry 24(10): 2190-2198. [34] Federica, T., Filippo, A., Petr, V., Tiziana, P., Peña-Méndez, E. M. and Josef, H. (2015). Coordination compounds in cancer: Past, present and perspectives. Journal of Applied Biomedicine13: 79-103.